Skip to main content

Weight Watchers Expands Med+ With Access to New Ozempic® pill (semaglutide)

Written by Customer Service on . Posted in Public Companies.

The addition of Ozempic® pill will give Weight Watchers Med+ members a new FDA-approved oral GLP-1 option for adults living with type 2 diabetes

NEW YORK, May 01, 2026 (GLOBE NEWSWIRE) — WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight management, announced that it will begin offering access to Novo Nordisk’s now available Ozempic® pill (semaglutide) through its Med+ offering and affiliated medical groups. The addition will give members a once-daily GLP-1 option for adults living with type 2 diabetes, further expanding Weight Watchers’ growing portfolio of oral GLP-1 treatments available through a clinically supported program designed to help members succeed.

Novo Nordisk first introduced Ozempic® in the U.S. as an injectable GLP-1 for adults with type 2 diabetes, and the brand has since become one of the most widely recognized names in the category. The Ozempic® pill builds on that foundation, offering a once-daily semaglutide option for adults with type 2 diabetes. With widespread insurance coverage of Ozempic, many eligible members can leverage their pharmacy benefits to make monthly prescription costs as low as $25. Weight Watchers supports members as they navigate prior authorization and utilization management requirements in order to help them find the best option whether that be insurance or cash pay.

“For adults living with type 2 diabetes, finding comprehensive support is extremely important, including clinical guidance, appropriate medication, insurance navigation and day-to-day tools” said Jon Volkmann, Chief Operations Officer at Weight Watchers. “With the addition of Ozempic® pill to our formulary, Weight Watchers Med+ is giving eligible members access to another FDA-approved semaglutide option, supported by clinicians and a care team who can help them navigate insurance and by a broader program designed to support diabetes care in everyday life.”

The launch reflects Weight Watchers’ continued focus on expanding access to trusted, brand-name GLP-1 medications while pairing treatment with comprehensive support designed for real life. Through Weight Watchers Med+, clinically eligible members will be able to access Ozempic® pill alongside care from board-certified clinicians, insurance support, and additional tools designed to support the treatment journey. Members also receive access to the Weight Watchers Diabetes Support program, with tailored nutrition guidance for individuals living with diabetes, coaching, virtual and in real life community, and access to a blood sugar tracker to see patterns and changes in blood sugar over time. In a study of 136 individuals, members on the Weight Watchers diabetes nutrition program experienced a 0.75% reduction in HbA1c after 6 months.

“If you’re living with type 2 diabetes, having options matters and the newly available, FDA-approved Ozempic® pill is another way we’re supporting people by offering a choice that fits into their daily routine,” said Ed Cinca, senior vice president of Marketing & Patient Solutions at Novo Nordisk Inc. “Partnering with Weight Watchers helps broaden patient access, with the coaching and clinical support members can lean on to feel confident as they navigate treatment.”

ABOUT WEIGHT WATCHERS
Weight Watchers is the global leader in science-backed weight management, offering an integrated support system built for the GLP-1 era that combines scientific expertise, medication, cutting-edge technology, and human connection. With more than 60 years of experience, Weight Watchers is the most studied commercial weight management program in the world, delivered through its No. 1 U.S. doctor-recommended weight-loss program. Its holistic, personalized approach also includes U.S.-based clinical interventions and access to GLP-1 medications when clinically appropriate, and a global network of coaches and community support. Since 1963, the company has led with science to deliver its members the personalized support they need to reach and sustain their goals. Members can access these solutions directly, or through Weight Watchers for Business’ full-spectrum platform for employers, health plans, and payers. In a landscape crowded with contradictory advice, isolating apps, and one-size-fits-all solutions, Weight Watchers offers a proven path forward that is rooted in research, grounded in empathy and designed to help every member feel better in their body and live a longer, healthier life. For more information, visit weightwatchers.com.

For investor inquiries, please contact:
John Mills or Anna Kate Heller
WeightWatchers@icrinc.com

For media inquiries, please contact:
Lizzy Levitan
WW@hunt-gather.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.